Ozgene

Executive Summary

Ozgene is a leading Australian contract research organization specializing in the design, generation, and phenotyping of genetically engineered mouse and rat models for biomedical research. Founded in 1999 and based in Perth, the company has established itself as a key enabler of preclinical studies across oncology, immunology, neuroscience, metabolic disorders, and infectious diseases. Ozgene's competitive edge lies in its proprietary goGermline™ embryonic stem cell technology and the OzBIG platform, which enables the insertion of large human genomic sequences up to 240 kb—a capability that significantly accelerates model creation while adhering to the 3Rs (Replacement, Reduction, Refinement) principles. With a workforce of 200–500 employees, the company provides comprehensive colony management services to a diverse client base spanning academia, biotech, and pharmaceutical companies worldwide. Ozgene's focus on faster, more efficient model generation positions it well to capitalize on the growing demand for humanized animal models in drug discovery. As precision medicine and complex therapeutic targets—such as immuno-oncology and gene therapies—gain traction, researchers require increasingly sophisticated models that recapitulate human biology. Ozgene's OzBIG platform directly addresses this need by allowing large human gene insertions, reducing the time from concept to validated model. While the company operates in a competitive CRO landscape, its technological differentiation and long-standing reputation in the field suggest steady growth potential. However, as a private entity with limited public financial disclosures, visibility into near-term performance is constrained. Overall, Ozgene represents a solid, niche player in the preclinical model space with room for expansion through partnerships and platform extensions.

Upcoming Catalysts (preview)

• Q3 2026Expansion of OzBIG platform into neuroscience models60% success
• TBDMajor partnership with a top-20 pharmaceutical company50% success
• Q4 2026Launch of new humanized mouse models for emerging oncology targets70% success